Completed PHASE2 INTERVENTIONAL 3-arm NCT00674466

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

Sponsor: ConjuChem

Conditions Type 2 Diabetes Mellitus

Interventions 1.5 mg or 2.0 mg CJC-1134-PC Placebo

Updated 9 times since 2017 Last updated: May 2, 2017 Started: Mar 31, 2008 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Type 2 Diabetes Mellitus and is currently completed. ConjuChem leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ConjuChem

Data source: ConjuChem

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada